The announcement was made during the 21st BioMed Israel 2023, the premier international Life Science and HealthTech convention in Tel Aviv, which was attended by ADSCC’s senior officials including Dr. Fatima Al Kaabi, Executive Director of the Abu Dhabi Bone Marrow Transplant Programme; and Dr. Maysoon Alkaram, Chief Medical Officer.

Seegnal is based in Savyon, a town in the Greater Tel Aviv area.

During the convention, Dr. Fatima Al Kaabi delivered a presentation on Bedside Developments of New Cell Therapies and the strides accomplished in this field in the UAE, specifically the Abu Dhabi Stem Cells Centre from clinical trials and research to clinical practice. The delegation visit to Israel is in line with ADSCC’s strategic vision to establish global collaborations to enhance stem cells therapy and research in the region, while playing a major role in global advancements in precision medicine in partnership with leading healthcare and research institutions.

The new “Seegnal Point of Care” solution allows ADSCC’s physicians and pharmacists to provide, on the one hand, patient-tailored safe and efficient medication prescription, taking into consideration hundreds of patient-specific factors when analyzing the medication regime, and on the other hand, eradicate any potential adverse drug effects setting up a new bar for patient safety in the region.

It will also help provide an all-in-one, evidence-based precision medicine in line with ADSCC’s National Flagship Pharmacogenomics Programme embracing the most innovative drug-related pharmacogenetic decision support tools to enhance patients’ care while substantially reducing healthcare expenditures.